Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development

Singh, Aman; Shin, Young; Shah, Dhaval
November 2015
Pharmaceutical Research;Nov2015, Vol. 32 Issue 11, p3508
Academic Journal
Characterization and prediction of the pharmacokinetics (PK) and pharmacodynamics (PD) of Antibody-Drug Conjugates (ADCs) is challenging, since it requires simultaneous quantitative understanding about the PK-PD properties of three different molecular species i.e., the monoclonal antibody, the drug, and the conjugate. Mathematical modeling and simulation provides an excellent tool to overcome these challenges, as it can simultaneously integrate the PK-PD of ADCs and their components in a quantitative manner. Additionally, the computational PK-PD models can also serve as a cornerstone for the model-based drug development and preclinical-to-clinical translation of ADCs. To provide an overview of this subject matter, this manuscript reviews the PK-PD models applicable to ADCs. Additionally, the usage of these models during different drug development stages ( i.e., discovery, preclinical development, and clinical development) is also emphasized. The importance of PK-PD modeling and simulation in making rationale go/no-go decisions throughout the drug development process is also highlighted. There is an array of PK-PD models available, ranging from the systems models specifically developed for ADCs to the empirical models applicable to all chemotherapeutic agents, which one can employ for ADCs. The decision about which model to choose depends on the questions to be answered, time at hand, and resources available.


Related Articles

  • Antibody-Drug Conjugates. Ritter, Amy // Pharmaceutical Technology;Jan2012, Vol. 36 Issue 1, p42 

    The article focuses on the development of antibody-drug conjugates (ADCs). It says that cytotoxins used in ADCs are more potent than the molecules used before such as doxorubicin. It states that experiences on monoclonal antibodies (mAbs) therapies were applied by developers in creating ADCs....

  • Antibody Drug Conjugates: A Marriage of Biologics and Small Molecules. Van Arnum, Patricia // Pharmaceutical Technology;Jun2008, Vol. 32 Issue 6, p54 

    The article focuses on the importance of antibody drug conjugates (ADCs) as part of anticancer drug development in the U.S. It cites that ADCs, or monoclonal antibodies linked to a cytotoxic small molecule, provide a niche opportunity for biopharmaceutical companies and contract manufacturers....

  • Antibody-Drug Conjugates. Kulkarni, Ashutosh; Gukasyan, Hovhannes // Pharmaceutical Research;Nov2015, Vol. 32 Issue 11, p3451 

    No abstract available.

  • Current ADC Linker Chemistry. Jain, Nareshkumar; Smith, Sean; Ghone, Sanjeevani; Tomczuk, Bruce // Pharmaceutical Research;Nov2015, Vol. 32 Issue 11, p3526 

    The list of ADCs in the clinic continues to grow, bolstered by the success of first two marketed ADCs: ADCETRIS® and Kadcyla®. Currently, there are 40 ADCs in various phases of clinical development. However, only 34 of these have published their structures. Of the 34 disclosed structures,...

  • Linkers Having a Crucial Role in Antibody-Drug Conjugates. Jun Lu; Feng Jiang; Aiping Lu; Ge Zhang // International Journal of Molecular Sciences;2016, Vol. 17 Issue 4, p561 

    Antibody-drug conjugates (ADCs) comprised of a desirable monoclonal antibody, an active cytotoxic drug and an appropriate linker are considered to be an innovative therapeutic approach for targeted treatment of various types of tumors and cancers, enhancing the therapeutic parameter of the...

  • Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Junutula, Jagath R; Raab, Helga; Clark, Suzanna; Bhakta, Sunil; Leipold, Douglas D; Weir, Sylvia; Chen, Yvonne; Simpson, Michelle; Tsai, Siao Ping; Dennis, Mark S; Lu, Yanmei; Meng, Y Gloria; Ng, Carl; Yang, Jihong; Lee, Chien C; Duenas, Eileen; Gorrell, Jeffrey; Katta, Viswanatham; Kim, Amy; McDorman, Kevin // Nature Biotechnology;Aug2008, Vol. 26 Issue 8, p925 

    Antibody-drug conjugates enhance the antitumor effects of antibodies and reduce adverse systemic effects of potent cytotoxic drugs. However, conventional drug conjugation strategies yield heterogenous conjugates with relatively narrow therapeutic index (maximum tolerated dose/curative dose)....

  • Semi-mechanistic Population Pharmacokinetic Model of Multivalent Trastuzumab Emtansine in Patients with Metastatic Breast Cancer. Chudasama, V L; Schaedeli Stark, F; Harrold, J M; Tibbitts, J; Girish, S R; Gupta, M; Frey, N; Mager, D E // Clinical Pharmacology & Therapeutics;Oct2012, Vol. 92 Issue 4, p520 

    Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate (ADC) composed of multiple molecules of the antimicrotubule agent DM1 linked to trastuzumab, a humanized anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibody. Pharmacokinetics data from phase I (n = 52) and phase II...

  • Production, Novel Assay Development and Clinical Applications of Monoclonal Antibodies. Chiarella, Pieranna // Recent Patents on Anti-Cancer Drug Discovery;May2011, Vol. 6 Issue 2, p258 

    Since the advent of hybridoma technology 35 years ago, research on monoclonal antibodies has developed enormously. Monoclonal antibodies of mouse origin were the first to be produced and continue to be the most popular affinity reagents for investigating the proteome of all organisms. For their...

  • Management of Metastatic Breast Cancer with Second-Generation Antibody-Drug Conjugates: Focus on Glembatumumab Vedotin (CDX-011, CR011-vcMMAE). Vaklavas, Christos; Forero, Andres // BioDrugs;Jun2014, Vol. 28 Issue 3, p253 

    Exploiting the highly targeted nature of monoclonal antibodies to deliver selectively to tumor cells a cytotoxic payload is an attractive concept and the successful precedents of the recent past set the stage for broader applications in the future. Antibody-drug conjugates may currently hold an...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics